Literature DB >> 29911997

HIV-1 latent reservoir size and diversity are stable following brief treatment interruption.

D Brenda Salantes1, Yu Zheng2, Felicity Mampe1, Tuhina Srivastava1, Subul Beg3, Jun Lai3, Jonathan Z Li2, Randall L Tressler4, Richard A Koup5, James Hoxie1, Mohamed Abdel-Mohsen6, Scott Sherrill-Mix1, Kevin McCormick1, E Turner Overton7, Frederic D Bushman1, Gerald H Learn1, Robert F Siliciano3,8, Janet M Siliciano3, Pablo Tebas1, Katharine J Bar1.   

Abstract

BACKGROUND: The effect of a brief analytical treatment interruption (ATI) on the HIV-1 latent reservoir of individuals who initiate antiretroviral therapy (ART) during chronic infection is unknown.
METHODS: We evaluated the impact of transient viremia on the latent reservoir in participants who underwent an ATI and at least 6 months of subsequent viral suppression in a clinical trial testing the effect of passive infusion of the broadly neutralizing Ab VRC01 during ATI.
RESULTS: Measures of total HIV-1 DNA, cell-associated RNA, and infectious units per million cells (IUPM) (measured by quantitative viral outgrowth assay [QVOA]) were not statistically different before or after ATI. Phylogenetic analyses of HIV-1 env sequences from QVOA and proviral DNA demonstrated little change in the composition of the virus populations comprising the pre- and post-ATI reservoir. Expanded clones were common in both QVOA and proviral DNA sequences. The frequency of clonal populations differed significantly between QVOA viruses, proviral DNA sequences, and the viruses that reactivated in vivo.
CONCLUSIONS: The results indicate that transient viremia from ATI does not substantially alter measures of the latent reservoir, that clonal expansion is prevalent within the latent reservoir, and that characterization of latent viruses that can reactivate in vivo remains challenging. TRIAL REGISTRATION: ClinicalTrials.gov NCT02463227FUNDING. Funding was provided by the NIH.

Entities:  

Keywords:  AIDS/HIV; Clinical Trials; T cells

Mesh:

Substances:

Year:  2018        PMID: 29911997      PMCID: PMC6026010          DOI: 10.1172/JCI120194

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

1.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.

Authors:  D Finzi; J Blankson; J D Siliciano; J B Margolick; K Chadwick; T Pierson; K Smith; J Lisziewicz; F Lori; C Flexner; T C Quinn; R E Chaisson; E Rosenberg; B Walker; S Gange; J Gallant; R F Siliciano
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

2.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

3.  Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies.

Authors:  Amanda M Crooks; Rosalie Bateson; Anna B Cope; Noelle P Dahl; Morgan K Griggs; JoAnn D Kuruc; Cynthia L Gay; Joseph J Eron; David M Margolis; Ronald J Bosch; Nancie M Archin
Journal:  J Infect Dis       Date:  2015-04-15       Impact factor: 5.226

4.  Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption.

Authors:  Meghan K Rothenberger; Brandon F Keele; Stephen W Wietgrefe; Courtney V Fletcher; Gregory J Beilman; Jeffrey G Chipman; Alexander Khoruts; Jacob D Estes; Jodi Anderson; Samuel P Callisto; Thomas E Schmidt; Ann Thorkelson; Cavan Reilly; Katherine Perkey; Thomas G Reimann; Netanya S Utay; Krystelle Nganou Makamdop; Mario Stevenson; Daniel C Douek; Ashley T Haase; Timothy W Schacker
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-23       Impact factor: 11.205

5.  Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells.

Authors:  Guinevere Q Lee; Nina Orlova-Fink; Kevin Einkauf; Fatema Z Chowdhury; Xiaoming Sun; Sean Harrington; Hsiao-Hsuan Kuo; Stephane Hua; Hsiao-Rong Chen; Zhengyu Ouyang; Kavidha Reddy; Krista Dong; Thumbi Ndung'u; Bruce D Walker; Eric S Rosenberg; Xu G Yu; Mathias Lichterfeld
Journal:  J Clin Invest       Date:  2017-06-19       Impact factor: 14.808

6.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

7.  Evaluating Clonal Expansion of HIV-Infected Cells: Optimization of PCR Strategies to Predict Clonality.

Authors:  Sarah B Laskey; Christopher W Pohlmeyer; Katherine M Bruner; Robert F Siliciano
Journal:  PLoS Pathog       Date:  2016-08-05       Impact factor: 6.823

8.  Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals.

Authors:  Katherine E Clarridge; Jana Blazkova; Kevin Einkauf; Mary Petrone; Eric W Refsland; J Shawn Justement; Victoria Shi; Erin D Huiting; Catherine A Seamon; Guinevere Q Lee; Xu G Yu; Susan Moir; Michael C Sneller; Mathias Lichterfeld; Tae-Wook Chun
Journal:  PLoS Pathog       Date:  2018-01-11       Impact factor: 6.823

9.  Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay.

Authors:  Gregory M Laird; Evelyn E Eisele; S Alireza Rabi; Jun Lai; Stanley Chioma; Joel N Blankson; Janet D Siliciano; Robert F Siliciano
Journal:  PLoS Pathog       Date:  2013-05-30       Impact factor: 6.823

10.  Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV Remission.

Authors:  Mykola Pinkevych; Deborah Cromer; Martin Tolstrup; Andrew J Grimm; David A Cooper; Sharon R Lewin; Ole S Søgaard; Thomas A Rasmussen; Stephen J Kent; Anthony D Kelleher; Miles P Davenport
Journal:  PLoS Pathog       Date:  2016-08-25       Impact factor: 6.823

View more
  49 in total

1.  Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.

Authors:  Boris Julg; Lynda Dee; Jintanat Ananworanich; Dan H Barouch; Katharine Bar; Marina Caskey; Donn J Colby; Liza Dawson; Krista L Dong; Karine Dubé; Joseph Eron; John Frater; Rajesh T Gandhi; Romas Geleziunas; Philip Goulder; George J Hanna; Richard Jefferys; Rowena Johnston; Daniel Kuritzkes; Jonathan Z Li; Udom Likhitwonnawut; Jan van Lunzen; Javier Martinez-Picado; Veronica Miller; Luis J Montaner; Douglas F Nixon; David Palm; Giuseppe Pantaleo; Holly Peay; Deborah Persaud; Jessica Salzwedel; Karl Salzwedel; Timothy Schacker; Virginia Sheikh; Ole S Søgaard; Serena Spudich; Kathryn Stephenson; Jeremy Sugarman; Jeff Taylor; Pablo Tebas; Caroline T Tiemessen; Randall Tressler; Carol D Weiss; Lu Zheng; Merlin L Robb; Nelson L Michael; John W Mellors; Steven G Deeks; Bruce D Walker
Journal:  Lancet HIV       Date:  2019-03-15       Impact factor: 12.767

2.  Genetic Diversity, Compartmentalization, and Age of HIV Proviruses Persisting in CD4+ T Cell Subsets during Long-Term Combination Antiretroviral Therapy.

Authors:  Bradley R Jones; Rachel L Miller; Jeffrey B Joy; Zabrina L Brumme; Natalie N Kinloch; Olivia Tsai; Hawley Rigsby; Hanwei Sudderuddin; Aniqa Shahid; Bruce Ganase; Chanson J Brumme; Marianne Harris; Art F Y Poon; Mark A Brockman; Rémi Fromentin; Nicolas Chomont
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

3.  Impact of Treatment Interruption on HIV Reservoirs and Lymphocyte Subsets in Individuals Who Initiated Antiretroviral Therapy During the Early Phase of Infection.

Authors:  Erin D Huiting; Kathleen Gittens; J Shawn Justement; Victoria Shi; Jana Blazkova; Erika Benko; Colin Kovacs; Paul A Wender; Susan Moir; Michael C Sneller; Anthony S Fauci; Tae-Wook Chun
Journal:  J Infect Dis       Date:  2019-06-19       Impact factor: 5.226

4.  Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors.

Authors:  Sean C Patro; Leah D Brandt; Michael J Bale; Elias K Halvas; Kevin W Joseph; Wei Shao; Xiaolin Wu; Shuang Guo; Ben Murrell; Ann Wiegand; Jonathan Spindler; Castle Raley; Christopher Hautman; Michele Sobolewski; Christine M Fennessey; Wei-Shau Hu; Brian Luke; Jenna M Hasson; Aurelie Niyongabo; Adam A Capoferri; Brandon F Keele; Jeff Milush; Rebecca Hoh; Steven G Deeks; Frank Maldarelli; Stephen H Hughes; John M Coffin; Jason W Rausch; John W Mellors; Mary F Kearney
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-27       Impact factor: 11.205

5.  Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption.

Authors:  Marie-Angélique De Scheerder; Clarissa Van Hecke; Henrik Zetterberg; Dietmar Fuchs; Nele De Langhe; Sofie Rutsaert; Bram Vrancken; Wim Trypsteen; Ytse Noppe; Bea Van Der Gucht; Jolanda Pelgrom; Filip Van Wanzeele; Sarah Palmer; Philippe Lemey; Magnus Gisslén; Linos Vandekerckhove
Journal:  J Antimicrob Chemother       Date:  2020-05-01       Impact factor: 5.790

6.  CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption.

Authors:  Justin Harper; Shari Gordon; Chi Ngai Chan; Hong Wang; Emily Lindemuth; Cristin Galardi; Shane D Falcinelli; Samuel L M Raines; Jenna L Read; Kevin Nguyen; Colleen S McGary; Michael Nekorchuk; Kathleen Busman-Sahay; James Schawalder; Colin King; Maria Pino; Luca Micci; Barbara Cervasi; Sherrie Jean; Andrew Sanderson; Brian Johns; A Alicia Koblansky; Heather Amrine-Madsen; Jeffrey Lifson; David M Margolis; Guido Silvestri; Katharine J Bar; David Favre; Jacob D Estes; Mirko Paiardini
Journal:  Nat Med       Date:  2020-03-16       Impact factor: 53.440

7.  Longitudinal study reveals HIV-1-infected CD4+ T cell dynamics during long-term antiretroviral therapy.

Authors:  Annukka Ar Antar; Katharine M Jenike; Sunyoung Jang; Danielle N Rigau; Daniel B Reeves; Rebecca Hoh; Melissa R Krone; Jeanne C Keruly; Richard D Moore; Joshua T Schiffer; Bareng As Nonyane; Frederick M Hecht; Steven G Deeks; Janet D Siliciano; Ya-Chi Ho; Robert F Siliciano
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

8.  Nonstructured Treatment Interruptions Are Associated With Higher Human Immunodeficiency Virus Reservoir Size Measured by Intact Proviral DNA Assay in People Who Inject Drugs.

Authors:  Gregory D Kirk; Jacqueline Astemborski; Shruti H Mehta; Kristen D Ritter; Gregory M Laird; Rebeka Bordi; Rafick Sekaly; Janet D Siliciano; Robert F Siliciano
Journal:  J Infect Dis       Date:  2021-06-04       Impact factor: 5.226

9.  Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption.

Authors:  Marcos V P Gondim; Scott Sherrill-Mix; Frederic Bibollet-Ruche; Ronnie M Russell; Stephanie Trimboli; Andrew G Smith; Yingying Li; Weimin Liu; Alexa N Avitto; Julia C DeVoto; Jesse Connell; Angharad E Fenton-May; Pierre Pellegrino; Ian Williams; Emmanouil Papasavvas; Julio C C Lorenzi; D Brenda Salantes; Felicity Mampe; M Alexandra Monroy; Yehuda Z Cohen; Sonya Heath; Michael S Saag; Luis J Montaner; Ronald G Collman; Janet M Siliciano; Robert F Siliciano; Lindsey J Plenderleith; Paul M Sharp; Marina Caskey; Michel C Nussenzweig; George M Shaw; Persephone Borrow; Katharine J Bar; Beatrice H Hahn
Journal:  Sci Transl Med       Date:  2021-01-13       Impact factor: 17.956

10.  Central Nervous System Safety During Brief Analytic Treatment Interruption of Antiretroviral Therapy Within 4 Human Immunodeficiency Virus Remission Trials: An Observational Study in Acutely Treated People Living With Human Immunodeficiency Virus.

Authors:  Joanna Hellmuth; Camilla Muccini; Donn J Colby; Eugène Kroon; Mark de Souza; Trevor A Crowell; Phillip Chan; Carlo Sacdalan; Jintana Intasan; Khunthalee Benjapornpong; Somporn Tipsuk; Suwanna Puttamaswin; Nitiya Chomchey; Victor Valcour; Michal Sarnecki; Frank Tomaka; Shelly J Krebs; Bonnie M Slike; Linda L Jagodzinski; Netsiri Dumrongpisutikul; Napapon Sailasuta; Vishal Samboju; Nelson L Michael; Merlin L Robb; Sandhya Vasan; Jintanat Ananworanich; Praphan Phanuphak; Nittaya Phanuphak; Robert Paul; Serena Spudich
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.